The online-ahead-of-print published article, “Azithromycin 1.5% Ophthalmic Solution for Blepharitis Treatment: Comparison of 14- Versus 30-Day Treatment,” by Altay Yesim, Demirok Gulizar, Balta Ozgur, and Bolu Hulya (DOI: 10.1089/jop.2015.0099) is being officially retracted from Journal of Ocular Pharmacology and Therapeutics (JOPT) due to post-publication authorship disputes and the discovery of simultaneous submission to both JOPT and the International Journal of Ophthalmology, which is a violation of the proper protocols of peer review.
Journal of Ocular Pharmacology and Therapeutics
and its editorial leadership are committed to maintaining the highest levels of scientific reporting and publishing, and therefore officially retracts the article based on the infringements listed herein.
Get full access to this article
View all access options for this article.
References
1.
OpitzD.L., and TylerK.F.Efficacy of azithromycin 1% ophthalmic solution for treatment of ocular surface disease from posterior blepharitis. Clin. Exp. Optom. 94:200–206, 2011.
2.
LempM.A., and NicholsK.K.Blepharitis in the United States 2009: a survey-based perspective on prevalence and treatment. Ocul. Surf. 7:S1–S14, 2009.
3.
RetsemaJ., GirardA., SchelklyW., et al.Spectrum and mode of action of azithromycin (CP-62,993), a new 15-membered ring macrolide with improved potency against gram-negative organisms. Antimicrob. Agents Chemother. 31:1939–1947, 1987.
4.
JainR., and DanzigerL.H.The macrolide antibiotics: a pharmacokinetic and pharmacodynamic overview. Curr. Pharm. Des. 10:3045–3053, 2004.
5.
IanaroA., IalentiA., MaffiaP., et al.Anti-inflammatory activity of macrolide antibiotics. J. Pharmacol. Exp. Ther. 292:156–163, 2000.
6.
AghaiZ.H., KodeA., SaslowJ.G., et al.Azithromycin suppresses activation of nuclear factor-kappa B and synthesis of pro-inflammatory cytokines in tracheal aspirate cells from premature infants. Pediatr. Res. 62:483–488, 2007.
7.
AkpekE.K., WittitowJ., VerhoevenR.S., et al.Ocular surface distribution and pharmacokinetics of a novel ophthalmic 1% azithromycin formulation. J. Ocul. Pharmacol. Ther. 25:433–439, 2009.
8.
StewartW.C., CreanC.S., ZinkR.C., et al.Pharmacokinetics of azithromycin and moxifloxacin in human conjunctiva and aqueous humor during and after the approved dosing regimen. Am. J. Ophthalmol. 150:744–751, 2010.
9.
FoulksG.N., BorchmanD., YappertM., KimS.H., and McKayJ.W.Topical azithromycin therapy of meibomian gland dysfunction: clinical response and lipid alterations. Cornea. 29:781–788, 2010.
10.
BronA.J., and TiffanyJ.M.The contribution of meibomian disease to dry eye. Ocul. Surf. 2:149–165, 2004.
11.
OlsonM.C., KorbD.R., and GreinerJ.V.Increase in tear film lipid layer thickness following treatment with warm compresses in patients with meibomian gland disfunction. Eye Contact Lens. 29:96–99, 2003.
12.
DoughertyJ.M., McCulleyJ.P., SilvanyR.E., and MeyerD.R.The role of tetracycline in chronic blepharitis. Inhibitation of lipase production in staphylococci. Invest. Ophthalmol. Vis. Sci., 32:2970–2975, 1991.
13.
RubinM., and RaoS.N.Efficacy of topical cyclosporin 0.05% in treatment of posterior blepharitis. J. Ocul. Pharmacol. Ther. 22:47–53, 2006.
14.
UtineC.A.Update and critical appraisal of the use of topical azithromycin ophthalmic 1% (Azasite) solution in the treatment of ocular infections. Clin. Ophthalmol. 5:801–809, 2011.
15.
O'DayD.M., HeadF.S., FouldsG., et al.Ocular pharmacokinetics of orally adminisrated azithromycin in rabbits. J. Ocul. Pharmacol. 10:633–641, 1994.
16.
TabbaraK.F., Al-KharashiS.A., Al-MansouriS.M., et al.Ocular levels of azithromycin. Arch. Ophthalmol. 116:1625–1628, 1998.
17.
LiD.Q., ZhouN., ZhangL., MaP., and PflugfelderS.C.Suppressive effects of azithromycin on zymosan-induced production of proinflammatory mediators by human corneal epithelial cells. Invest. Ophthalmol. Vis. Sci. 51:5623–5629, 2010.
18.
HaqueR.Z., TorkildsenG.L., BrubakerK., et al.Multicenter open-label study evaluating the efficacy of azithromycin ophthalmic solution 1% on signs and symptoms of subjects with blepharitis. Cornea. 29:871–877, 2010.
19.
LuchsJ.Efficacy of topical azithromycin ophthalmic solution 1% in the treatment of posterior blepharitis. Adv. Ther. 25:858–870, 2008.
20.
FadlallahA., RamiH.L., FahdD., et al.Azithromycin 1.5% ophthalmic solution: efficacy and treatment modalities in chronic blepharitis. Arq. Bras. Opthalmol. 75:178–182, 2012.
